Page 256 - பல்கலைக்கழகம் ஆரோக்கியம் வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers test effects of full doses of anticoagulants in COVID-19 patients Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, full-dose anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials. As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders. Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.

Ryan zarychanskiEwan goligherEmily hendersonUniversity of torontoHospital research instituteUniversity health networkAdaptive platform trial for communityUniversity of manitobaCancercare manitobaMulti factorial adaptive platform trialCommunity acquired pneumoniaTherapeutic anticoagulationAntithrombotics inpatientAntithrombotic therapyAmeliorate complicationsAssistant professor